| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/TP.0000000000000184 |
| P698 | PubMed publication ID | 24839895 |
| P2093 | author name string | Eric Rondeau | |
| Alexandre Hertig | |||
| Laurent Mesnard | |||
| Karine Dahan | |||
| Caroline Suberbielle | |||
| Christophe Ridel | |||
| Isabelle Brochériou | |||
| Maren Burbach | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1056-1059 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts | |
| P478 | volume | 98 |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q36302476 | An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA |
| Q38392458 | Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management |
| Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
| Q40417954 | C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study |
| Q42086661 | Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea |
| Q39730025 | Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients |
| Q39371134 | Complement in Kidney Transplantation |
| Q38609238 | Complement inhibition as potential new therapy for antibody-mediated rejection. |
| Q46970385 | Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment |
| Q33829159 | Complement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003 |
| Q47563660 | Desensitisation strategies in high-risk children before kidney transplantation. |
| Q49264301 | Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation |
| Q38914719 | Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature. |
| Q51121337 | Effects of alloantibodies to human leukocyte antigen on endothelial expression and serum levels of thrombomodulin. |
| Q26995453 | Effects of complement activation on allograft injury |
| Q40266578 | HLA Class II Antibody Activation of Endothelial Cells Promotes Th17 and Disrupts Regulatory T Lymphocyte Expansion |
| Q36417907 | IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury |
| Q27010224 | Modern approaches to incompatible kidney transplantation |
| Q27314948 | Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms |
| Q39968188 | Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field |
| Q47104714 | Pharmacologic Complement Inhibition in Clinical Transplantation. |
| Q89721385 | Plasma Cell-Rich Acute Rejection in Renal Transplantation: A Case Report |
| Q42364725 | Stratification of responders towards eculizumab using a structural epitope mapping strategy |
| Q33415999 | Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis |
| Q28087773 | The Complement System and Antibody-Mediated Transplant Rejection |
| Q50062896 | The mechanisms of rejection in solid organ transplantation |
| Q58115660 | The multifaceted role of complement in kidney transplantation |
| Q64930201 | The role of C4d deposition in the diagnosis of antibody-mediated rejection after lung transplantation. |
Search more.